Key Developments: Dainippon Sumitomo Pharma Co Ltd (4506.T)
1,522JPY
24 May 2013
¥-43 (-2.75%)
¥1,731
¥1,580
¥1,616
¥1,468
3,369,800
2,314,484
¥1,920
¥731
Latest Key Developments (Source: Significant Developments)
Dainippon Sumitomo Pharma Co., Ltd. Amends Consolidated Full-year Outlook for FY 2012 Below Analysts' Estimate
Dainippon Sumitomo Pharma Co., Ltd. announced that it has affirmed its consolidated full-year outlook for revenue of JPY 352,000 million, but raised the outlook for operating profit from JPY 20,000 million to JPY 22,000 million and ordinary profit form JPY 19,000 million to JPY 22,000 million, and lowered the outlook for net profit from JPY 12,000 million to JPY 10,000 million and earning per share from JPY 30.20 to JPY 25.17, for the fiscal year ending March 2012. The Company raised the operating profit and ordinary profit outlook due to the cost reduction, and lowered the net profit outlook due to the record of extraordinary loss and the increased tax cost, among others. According to I/B/E/S Estimates, analysts were expecting the Company to report full-year revenue of JPY 356.02 billion and net profit of JPY 12.24 billion. Full Article
R&I Affirms Rating on Dainippon Sumitomo Pharma Co., Ltd. at "A"; Rating Outlook Stable
Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Dainippon Sumitomo Pharma Co., Ltd. at "A". The rating outlook is stable. Full Article
Dainippon Sumitomo Pharma Co., Ltd. Amends FY 2012 Outlook
Dainippon Sumitomo Pharma Co., Ltd. announced that it has lowered its consolidated full-year outlook for revenue from JPY 362,000 million to JPY 352,000 million, and raised its consolidated full-year outlook for operating profit from JPY 17,000 million to JPY 20,000 million, ordinary profit from JPY 15,500 million to JPY 19,000 million, net profit from JPY 8,500 million to JPY 12,000 million and earning per share from JPY 21.39 to JPY 30.20 for the fiscal year ending March 2012. This is due to the influence of the high Japanese yen, the decreased selling, general administrative, research and development expenses, as well as the recording of JPY 1.2 billion profit on sale of fixed assets as extraordinary profit. According to I/B/E/S Estimates, analysts on average are expecting the Company to report full-year revenue of JPY 361.05 billion and net profit of JPY 11.20 billion. Full Article
Dainippon Sumitomo Pharma Co., Ltd. to Issue Unsecured Bond
Dainippon Sumitomo Pharma Co., Ltd. announced that it will issue JPY 10 billion fourth series unsecured bonds, each with a face value of JPY 100 million. The details regarding the bond issue are as follows: maturity on September 8, 2016, interest rate 0.535%, subscription on September 2, 2011 and payment on September 8, 2011. The Company will also issue JPY 10 billion fifth series bonds, each with a face value of JPY 100 million. The details regarding the bond issue are as follows: maturity on September 7, 2018, interest rate 0.821%, subscription on September 2, 2011 and payment on September 8, 2011. Daiwa Securities Capital Markets Co. Ltd., Nomura Securities Co.,Ltd. and SMBC Nikko Securities Inc. will be working as underwriters for the offering. Full Article
Dainippon Sumitomo Pharma Co., Ltd. and KYORIN Holdings, Inc. Announce Results of Domestic PII Trial of Ranirestat-Jiho, Inc.
Jiho, Inc. reported that Dainippon Sumitomo Pharma (DSP) and Kyorin Holdings (HD) have announced the results of a PIIb clinical trial of ranirestat, which is being developed jointly by DSP and Kyorin Pharmaceutical in Japan for the treatment of diabetic complications. Although the total nerve conduction velocity, an indication for the improvement of diabetic peripheral neuropathy which served as the primary endpoint, did not show any clear dose response, it increased significantly in all groups administered ranirestat compared to pre-treatment baseline. Discovered by DSP, ranirestat is expected to improve diabetic neuropathy, a major diabetic complication, by potently inhibiting aldose reductase and thereby preventing intracellular accumulation of sorbitol. Full Article
DeNA Co., Ltd. Signs Development Agreement with Dainippon Sumitomo Pharma Co.,Ltd
DeNA Co., Ltd. announced that it has signed a development agreement with Dainippon Sumitomo Pharma Co.,Ltd on June 7, 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
